|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
207.22(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,592,266 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$56,317,001 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
60 |
103 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Auster Martin |
Chief Financial Officer |
|
2022-12-02 |
4 |
S |
$29.01 |
$2,832,603 |
D/D |
(97,647) |
47,649 |
|
-3% |
|
Auster Martin |
Chief Financial Officer |
|
2022-12-02 |
4 |
OE |
$3.45 |
$172,500 |
D/D |
50,000 |
145,296 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2022-12-01 |
4 |
S |
$29.01 |
$3,751,150 |
I/I |
(129,317) |
16,616,048 |
|
-4% |
|
Subramaniam Somu |
Director |
|
2022-12-01 |
4 |
S |
$29.01 |
$3,751,150 |
I/I |
(129,317) |
16,616,048 |
|
-4% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2022-11-30 |
4 |
S |
$29.01 |
$4,155,732 |
I/I |
(143,228) |
16,745,365 |
|
-3% |
|
Subramaniam Somu |
Director |
|
2022-11-30 |
4 |
S |
$29.01 |
$4,155,732 |
I/I |
(143,228) |
16,745,365 |
|
-3% |
|
Subramaniam Somu |
Director |
|
2022-11-07 |
4 |
S |
$29.08 |
$114,427 |
I/I |
(3,935) |
16,888,593 |
|
-52% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2022-11-07 |
4 |
S |
$29.08 |
$114,427 |
I/I |
(3,935) |
16,888,593 |
|
-52% |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-08-23 |
4 |
OE |
$0.20 |
$33,872 |
D/D |
169,361 |
352,692 |
|
- |
|
Sandborn William J. |
See RemarksOfficer |
|
2022-05-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
34,877 |
|
147% |
|
Sandborn William J. |
See RemarksOfficer |
|
2022-05-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
48,389 |
|
147% |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-04-03 |
4 |
AS |
$32.88 |
$493,166 |
D/D |
(15,000) |
276,117 |
|
39% |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-04-03 |
4 |
OE |
$3.54 |
$32,040 |
D/D |
8,447 |
291,117 |
|
- |
|
Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
|
2021-10-25 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
1,410,303 |
1.5 |
-33% |
|
Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
I/I |
785,303 |
785,303 |
|
- |
|
Royston Aaron |
Director |
|
2021-10-25 |
4 |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
3,997,269 |
2.25 |
-33% |
|
Royston Aaron |
Director |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,684,769 |
3,684,769 |
|
- |
|
Goodman Corey S |
See Remarks |
|
2021-10-25 |
4 |
B |
$16.00 |
$5,000,000 |
D/D |
312,500 |
3,997,269 |
2.45 |
-33% |
|
Goodman Corey S |
See Remarks |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,684,769 |
3,684,769 |
|
- |
|
Subramaniam Somu |
Director |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
I/I |
16,892,528 |
16,892,528 |
|
- |
|
Gujrathi Sheila |
Director |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
32,897 |
32,897 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2021-10-25 |
4 |
A |
$0.00 |
$0 |
I/I |
16,892,528 |
16,892,528 |
|
- |
|
Nuss John |
Chief Scientific OfficerOffice |
|
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
308,696 |
|
- |
|
Mohan Raju |
Chief Executive OfficerOfficer |
|
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,841,811 |
|
- |
|
Krueger Christopher W |
Chief Business OfficerOfficer |
|
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
183,331 |
|
- |
|
178 Records found
|
|
Page 7 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|